Advaxis to Present at Upcoming March Conferences
March 13 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage
biotechnology company (“Advaxis” or the “Company”) focused on the
discovery, development and commercialization of cancer
immunotherapies, announced today that Company management will
present at the following upcoming March 2018 conferences:
Barclays Global Healthcare Conference
- Date and Time: Thursday, March
15, 2018 at 9:30am ET
- Venue: Loews Miami Beach
Hotel, Miami, FL
- Presenter: Anthony Lombardo,
Interim Chief Executive Officer
- Presentation: Company
overview
25th Annual Future Leaders in the Biotech
Industry Conference
- Date and Time: Friday, March
23rd at 3:00pm ET
- Venue: Millennium Broadway
Hotel & Conference Center, New York, NY
- Presenter: Robert Petit, Ph.D.,
EVP and Chief Scientific Officer
- Presentation: Company
overview
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains integrate multiple functions into
a single immunotherapy, and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and near-clinical
development: HPV-associated cancers, individualized neoantigen
immunotherapy, cancer-specific hotspot mutation immunotherapies and
prostate cancer.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180313005417/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsAnne Marie Fields,
212-838-3777afields@lhai.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024